Apollomics Reports First Half 2023 Financial Results and

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half...

Related Keywords

Beijing ,China ,United States ,Kunpeng ,Guangdong ,Guo Liang Yu ,Peter Vozzo ,Sean Leous ,Exchange Commission ,Maxpro Capital Acquisition Corp ,Nasdaq ,Securities Exchange ,Us National Cancer Institute ,Apollomics Inc ,China National Medical Products Administration ,Chief Executive Officer ,Drug Administration ,Beijing Pearl ,Breakthrough Therapy ,Cancer Institute ,Maxpro Capital Acquisition ,Apollomic Class ,Nasdaq Capital Market ,Results Conference ,Securities Act ,Securities Exchange Act ,Annual Report ,Registration Statement ,Nasdaq Aplm ,